Physician profile
Mark S Diamond
NPI 1073514113
$93,410.52
in general payments reported to CMS, 2019-2025
87 companies · $1,951 in 2025
The $1,951 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,107 · 2020: $14K · 2021: $40K · 2022: $22K · 2023: $8,298 · 2024: $4,820 · 2025: $1,951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,500 · Food and Beverage: $6,468 · Education: $68.24 · Travel and Lodging: $32.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,500.00 |
| Food and Beverage | $6,467.53 |
| Education | $68.24 |
| Travel and Lodging | $32.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,426.23 | 2021-2025 | Ubrelvy, Qulipta, Botox |
| Biohaven Pharmaceuticals, INC. | $20,719.11 | 2020-2021 | |
| Allergan, INC. | $15,424.49 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14,288.66 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $1,493.73 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $911.80 | 2019-2025 | |
| Pfizer INC. | $788.06 | 2019-2025 | |
| Biogen, INC. | $564.43 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Ucb, INC. | $556.93 | 2019-2025 | Briviact, Nayzilam, Rystiggo |
| Alexion Pharmaceuticals, INC. | $542.37 | 2019-2024 | Ultomiris, Soliris |
| Amgen INC. | $516.97 | 2019-2025 | Uplizna, Aimovig |
| Celgene Corporation | $501.85 | 2022-2025 | Zeposia |
| Neurocrine Biosciences, INC. | $427.34 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $425.85 | 2019-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $406.17 | 2019-2025 | Kisunla, Amyvid, Emgality |
Show all 87 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.